Abstracts system the combined screening/risk-based strategy and the risk-based strategy are efficient strategies with reasonable cost-effectiveness.
OBJECTIVES:
To estimate the incremental costeffectiveness ratio (ICER) of routine meningococcal serogroup C conjugate vaccination of children at 2, 3, and 4, or at 5 and 6 months instead of at 14 months in the Netherlands and to determine the impact of including herd-immunity. METHODS: The analysis was performed from a societal perspective and in accordance to the Dutch guidelines for pharmacoeconomic research, using a cohort model. Direct and indirect (friction cost method) costs were considered. Future costs and effects were discounted at 4% and 2000 was chosen as baseline year. A vaccine effectiveness of 90% (based on UK data) and a vaccine protection duration of 20 years (based on the experience with Haemophilus influenzae type b) were used. Also on the basis of UK data, we assumed that 70% of all unvaccinated persons aged 0-14 months are protected because of the herd-immunity effect caused by the recent meningococcal C conjugate vaccination of all persons aged 14 months to 18 years. RESULTS: For immunization of children at 2, 3, and 4 (5 + 6) months, the herd-immunity effect decreases the yearly number of additional life years gained from 51 (36) to 15 (11) but leads to a strong increase of the ICER from €149,000 (€105,000) per life year gained to €497,000 (€349,000) per life year gained. Even if only a herd-immunity effect of 50% is assumed, the ICER still increases to about €298,000 (€209,000) per life year gained. These results are sensitive to the protection duration and effectiveness of the vaccine and the meningococcal C incidence. CON-CLUSIONS: The inclusion of herd-immunity decreases the rendered small health gain and thus leads to even less favorable cost-effectiveness ratios for vaccination of children aged less than one year. Hence, the current Dutch vaccination strategy of routine vaccinating children at 14 months should not be changed. Respiratory syncytial virus (RSV) is a leading cause of a lower respiratory tract infection in infants and is responsible for increased hospitalization, morbidity, and deaths amongst high-risk individuals including those who are born prematurely. As the treatment of RSV infections is limited the analysis was focused on prophylactic therapy with palivizumab, a humanized murine monoclonal antibody that provides passive immunity against RSV. OBJECTIVES: To evaluate costs and cost-effectiveness of RSV prophylaxis among infants born at less than 32 weeks gestation in Poland. METHODS: Decision tree analysis was used to compare cost-effectiveness of two strategies, palivizumab and no prophylaxis, among a hypothetical cohort of infants born <32 gestational age. Probabilities were derived from published trials. Costs encompassed: drug costs, costs of non-intensive and intensive pediatric hospital care and costs of asthma treatment up to age 7. The discount rate of costs was set at 3%. The cost-effectiveness ratio was expressed as cost of life year gained with RSV prophylaxis. Sensitivity analyses were performed for the key probabilities. RESULTS: Palivizumab prophylaxis was estimated to cost €8903 per life gained as compared to €6594 for no preventive treatment. The incremental cost-effectiveness ratio of one life year gained amounted to €13,246 (PPP: €1 = 1.9 PLN). The sensitivity analysis indicated that the results were sensitive to the probability of hospitalization for RSV for no prophylaxis. CONCLUSIONS: Palivizumab, as compared to other widely accepted medical procedures, appeared to be cost-effective prophylaxis for the prevention of serious lower respiratory-tract infection caused by RSV in infants born at less than 32 weeks gestation in Poland.
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INTRODUCTION OF A NEW HEALTH TECHNOLOGY, POTENTIAL BEHAVIOURAL AND ORGANISATIONAL CHANGES AND POLICY IMPACT-ASSESSMENT OF NEW INFLUENZA TREATMENTS
Gyldmark M 1 , Sander B 2 1 F. Hoffman-La Roche Ltd, Basel, Switzerland; 2 Institute for Medical Outcome Research, Loerrach, Germany
OBJECTIVES:
The objective is to discuss and evaluate potential changes in patient, physician, and organisational behavior related to the introduction of a new health care technology (treatment of influenza with the anti-viral neuraminidase inhibitors). The changes evaluated are: 1) increased health care seeking by patients, due to the availability of antivirals for influenza; 2) Crowding out of inappropriate anti-biotic prescribing for influenza by antivirals; and 3) System change to allow telephone nurse prescribing rather than GP consultation. METHODS: Some unique characteristics of neuramindase inhibitors has important implications for their cost-effectiveness in any given health care systems. A health economic decision model is employed in order to evaluate some of these potential changes when introducing treatment of influenza with neuraminidase inhibitors. The impact on cost-effectiveness and cost-utility of three different behavioural changes are investigated with the model as well as the base line cost-effectiveness and cost-utility of treating healthy adults in UK. RESULTS: The results of the economic modeling show that treatment of influenza in healthy adults with the anti-viral oseltamivir has incremental cost-utility ratios between £4,775/QALY (baseline) and £15,772/QALY (increased health care seeking by patients). CONCLUSION: In order to make a decision regarding introduction of influenza treatment with the new technology a number of issues ought to be addressed. These may be best dealt with in a full HTA where all aspects of introducing a new technology are investigated. By only evaluating certain aspects of the introduction of the technology, decision makers are likely to make decisions based on incomplete information. This may result in sub-optimal patient treatment and resource use in society. 
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COST-EFFECTIVENESS ANALYSIS OF PEGYLATED INTERFERONS COMBINED WITH RIBAVIRIN IN THE TREATMENT OF HEPATITIS C
OBJETIVE:
The hepatitis C treatment with conventional interferon monotherapy has been under discussion because of its low response rate (10-20%). However, combination therapies involving ribavirin and the new two pegylated interferons have raised the response rates beyond 50%. This study analyses the cost-effectiveness ratios for two different peginterferons (peginterferon alfa-2a and peginterferon alfa-2b) plus ribavirin compared with interferon-alfa 2b plus ribavirin. METHOD: A Markov model was developed to represent the natural history of hepatitis C and to estimate the incremental cost-effectiveness ratios for the two different peginterferons plus ribavirin compared with interferon-alfa 2b plus ribavirin. The results of two indipendent clinical trials comparing these treatment alternatives in naive patients with HCV infection and no co-morbidity have been obtained from several publications. The model was applied separately to both trials. To evaluate the natural history of decompensated cirrhosis, 200 patients with decompensated liver disease from hepatitis C etiology were studied depending on the first decompensation event in two different hospitals in Spain. RESULTS: The results indicate costs of €20,751/life-year gained using efficacy data from the peginterferon alfa-2b trial and €10,350/lifeyear gained employing the peginterferon alfa-2a trial data. When a test is used at 12 weeks to facilitate an early detection of non-responders, the figures lower to €14,037 and €6,605/life-year gained, respectively. CONCLU-SION: The main conclusion is that the combined treatment of peginterferon plus ribavirin is cost-effective showing peginterferon alfa-2a a better cost-effectiveness ratio than peginterferon alfa-2b. Efficiency decreases with advancing age and can be increased when strategies of early selection are employed to identify those patients who, without sustained viral response, would not benefit from the treatment.
